Invention Title:

Systems and Methods for Cancer Screening

Publication number:

US20260337690

Publication date:
Section:

Chemistry; metallurgy

Class:

C12Q1/6886

Inventors:

Assignees:

Applicants:

Smart overview of the Invention

The proposed system leverages cell-free DNA (cfDNA) to enhance cancer screening processes. By extracting cfDNA from a biological sample, various features such as sequence variants, base modifications, and fragment lengths are identified. A machine-learning model then analyzes these features to ascertain the presence of cancer. This approach aims to provide a minimally invasive alternative to traditional imaging methods, addressing the limitations of current diagnostic practices.

Technological Context and Challenges

Traditional cancer screening methods, like mammography and ultrasound, often require significant time and can be uncomfortable, potentially leading to low compliance. The use of cfDNA offers a promising alternative due to its ease of collection through liquid biopsies, which involve simple blood draws. Despite the potential, conventional cfDNA analysis methods are limited by the need for large sample volumes and DNA amplification, which can introduce biases and damage the DNA.

Innovative Methodology

This invention employs single-molecule sequencing platforms, such as those from Oxford Nanopore Technologies and Pacific Biosciences, to analyze cfDNA without amplification. These platforms can simultaneously read nucleic acid sequences, detect base modifications, and measure fragment lengths, even with small DNA quantities. The method involves feeding identified cfDNA features into machine-learning models trained to detect cancer-specific patterns, thereby improving the accuracy and efficiency of cancer detection.

Applications and Benefits

  • Facilitates early detection and monitoring of various cancer types, including breast, lung, and prostate cancer.
  • Enables screening before symptoms appear and assesses residual disease post-treatment.
  • Offers a non-invasive, patient-friendly alternative to traditional diagnostic methods, enhancing compliance and early intervention.
  • Supports personalized medicine through detailed analysis of cancer-related characteristics such as tissue origin and cancer stage.

Clinical and Practical Implications

The use of cfDNA for cancer screening provides significant clinical advantages, including the ability to perform timely interventions and tailor treatments based on specific cancer characteristics. The method's reliance on liquid biopsies ensures a more comfortable and accessible screening process for patients, potentially leading to better outcomes through early detection. By integrating advanced sequencing technologies and machine learning, the system aims to revolutionize cancer diagnostics and management.